Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

BioScience Health Innovations (BHIC) FCF Margin (2023 - 2026)

BioScience Health Innovations has reported FCF Margin over the past 4 years, most recently at 73.52% for Q1 2026.

  • Quarterly FCF Margin fell 10028.0% to 73.52% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 13.59% through Mar 2026, down 2788.0% year-over-year, with the annual reading at 3.03% for FY2025, 177.0% up from the prior year.
  • FCF Margin was 73.52% for Q1 2026 at BioScience Health Innovations, down from 6.4% in the prior quarter.
  • Over five years, FCF Margin peaked at 26.76% in Q1 2025 and troughed at 206.18% in Q1 2023.
  • The 4-year median for FCF Margin is 17.31% (2024), against an average of 37.8%.
  • Year-over-year, FCF Margin soared 18888bps in 2024 and then tumbled -10028bps in 2026.
  • A 4-year view of FCF Margin shows it stood at 18.59% in 2023, then surged by 56bps to 8.24% in 2024, then increased by 22bps to 6.4% in 2025, then crashed by -1048bps to 73.52% in 2026.
  • Per Business Quant, the three most recent readings for BHIC's FCF Margin are 73.52% (Q1 2026), 6.4% (Q4 2025), and 30.09% (Q3 2025).